All In Biotech

Drug Trial Radar · NCT00806208

Trial for Evaluation of Safety of Escalating Dose Levels of MEDI-507 in Patients for Treatment of at Least Grade II Graft-Versus-Host Disease (GvHD)

Phase I Evaluation of Safety, Pharmacokinetics and Activity of Escalating Dose Levels of MEDI 507 in Patients Receiving Methylprednisolone for Initial Treatment of at Least Grade II Graft-Versus-Host Disease (GvHD)

Last checked: Nov 20, 2026Latest source record: Dec 11, 2008 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

34

Actual

Start

Jan 1999

Primary completion

Jan 2000

Study completion Mar 2000

Sponsor

Lead sponsor
MedImmune LLCAstraZeneca (AZN)
Sponsor type
Industry
First posted
Dec 10, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years

Summary

As written by the sponsor on the registry.

A trial to assess safety of four doses of MEDI 507 combined with another drug for initial treatment of at least Grade II acute Graft-vs-Host Disease in recipients.

Conditions

  • Graft-Versus-Host Disease

Interventions

  • MEDI-507Drug

    0.012 mg/kg MEDI 507 and Methylprednisolone

  • MEDI-507Drug

    0.04 mg/kg MEDI 507 and Methylprednisolone

  • MEDI-507Drug

    0.12 mg/kg MEDI 507 and Methylprednisolone

  • MEDI-507Drug

    0.4 mg/kg MEDI 507 and Methylprednisolone

  • PlaceboOther

    Placebo IV (alternative) study days 0, 3,6, and 9

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety; first infusion of study drugTime frame: Through Study Day 44

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Washington University Medical Center

    St Louis, Missouri

  • University of Nebraska Medical Center

    Omaha, Nebraska

  • Baylor Institute of Transplant Sciences

    Dallas, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.